A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease, COPD

In brief

To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)

Key facts

Study ID

NCT02449018

Run by

Novartis Pharmaceuticals

People needed

92

Starts

2015-04-30

Expected to finish

2017-01-23

Last updated by the study team

2021-01-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Novartis Investigative Site — Birmingham, Alabama, United States
• Novartis Investigative Site — Fullerton, California, United States
• Novartis Investigative Site — Waterbury, Connecticut, United States
• Novartis Investigative Site — Clearwater, Florida, United States
• Novartis Investigative Site — Port Orange, Florida, United States
• Novartis Investigative Site — Tampa, Florida, United States
• Novartis Investigative Site — Normal, Illinois, United States
• Novartis Investigative Site — St Louis, Missouri, United States
• Novartis Investigative Site — Huntersville, North Carolina, United States
• Novartis Investigative Site — Shelby, North Carolina, United States
• Novartis Investigative Site — Medford, Oregon, United States
• Novartis Investigative Site — Simpsonville, South Carolina, United States
• Novartis Investigative Site — Spartanburg, South Carolina, United States
• Novartis Investigative Site — Union, South Carolina, United States
• Novartis Investigative Site — Lodz, Poland
• Novartis Investigative Site — Sobótka, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.